What is the official website of Taro Pharmaceuticals ?

The official website of Taro Pharmaceuticals is http://www.taro.com.

What is Taro Pharmaceuticals's cybersecurity risk score?

Taro Pharmaceuticals has an AI-generated cybersecurity risk score of 724 out of 1000, indicating a Moderate security posture according to Rankiteo's assessment.

How many security incidents has Taro Pharmaceuticals experienced?

According to Rankiteo, Taro Pharmaceuticals currently holds 0 security badges, indicating that no recognized compliance certifications are currently verified for the organization.

Has Taro Pharmaceuticals been affected by any supply chain cyber incidents ?

According to Rankiteo, Taro Pharmaceuticals has not been affected by any supply chain cyber incidents, and no incident IDs are currently listed for the organization.

Does Taro Pharmaceuticals have SOC 2 Type 1 certification ?

According to Rankiteo, Taro Pharmaceuticals is not certified under SOC 2 Type 1.

Does Taro Pharmaceuticals have SOC 2 Type 2 certification ?

According to Rankiteo, Taro Pharmaceuticals does not hold a SOC 2 Type 2 certification.

Does Taro Pharmaceuticals comply with GDPR ?

According to Rankiteo, Taro Pharmaceuticals is not listed as GDPR compliant.

Does Taro Pharmaceuticals have PCI DSS certification ?

According to Rankiteo, Taro Pharmaceuticals does not currently maintain PCI DSS compliance.

Does Taro Pharmaceuticals comply with HIPAA ?

According to Rankiteo, Taro Pharmaceuticals is not compliant with HIPAA regulations.

Does Taro Pharmaceuticals have ISO 27001 certification ?

According to Rankiteo,Taro Pharmaceuticals is not certified under ISO 27001, indicating the absence of a formally recognized information security management framework.

Which industry does Taro Pharmaceuticals operate in ?

Taro Pharmaceuticals operates primarily in the Pharmaceutical Manufacturing industry.

How many employees does Taro Pharmaceuticals have ?

Taro Pharmaceuticals employs approximately 1,518 people worldwide.

Does Taro Pharmaceuticals own any subsidiaries ?

Taro Pharmaceuticals presently has no subsidiaries across any sectors.

How many LinkedIn followers does Taro Pharmaceuticals have ?

Taro Pharmaceuticals's official LinkedIn profile has approximately 40,119 followers.

What is the NAICS classification code for Taro Pharmaceuticals ?

Taro Pharmaceuticals is classified under the NAICS code 3254, which corresponds to Pharmaceutical and Medicine Manufacturing.

Does Taro Pharmaceuticals have a Crunchbase profile ?

No, Taro Pharmaceuticals does not have a profile on Crunchbase.

Does Taro Pharmaceuticals have a LinkedIn profile ?

Yes, Taro Pharmaceuticals maintains an official LinkedIn profile, which is actively utilized for branding and talent engagement, which can be accessed here: https://www.linkedin.com/company/taro-pharmaceuticals.

How many cybersecurity incidents has Taro Pharmaceuticals experienced ?

As of August 11, 2026, Rankiteo reports that Taro Pharmaceuticals has experienced 1 cybersecurity incidents.

How many peer or competitor companies does Taro Pharmaceuticals have ?

Taro Pharmaceuticals has an estimated 5,728 peer or competitor companies worldwide.

What types of cybersecurity incidents has Taro Pharmaceuticals faced ?

Incident Types: The types of cybersecurity incidents that have occurred include Breach.

NEWRankiteo Cyber Underwriting Desktop - Score, price, and bind from your desktop

WindowsmacOSLinux

Download

Badge your company to reduce your risk score and your cyber insurance costs!

Link verified badges to your company page to build trust with insurers and customers.

Apply now and get your badge!

Internal validation & live display

Insurers and partners see a safer profile

Faster underwriting decisions

Trusted by insurers. Chosen by leaders.

Proud contributor to the Society of Actuaries.

Taro Pharmaceuticals

Boost Score +25 with badge (5 left)

724

/1000

Moderate

749

/1000

Moderate

Taro Pharmaceuticals Vendor Cyber Rating & Cyber Score

taro.com

Add Your Compliance Badge

Established in 1950, Taro Pharmaceutical Industries Ltd. is a research-based, international, specialty pharmaceutical company that develops, manufactures and markets prescription and over-the-counter pharmaceutical products. Taro’s research programs and niche strategy have enabled the Company to achieve gross margins that are among the highest in the specialty pharmaceutical sector.

Taro Pharmaceuticals A.I CyberSecurity Scoring

Scoring History

Taro Pharmaceuticals

Taro Pharmaceuticals CyberSecurity News & History

Past Incidents

Attack Types

Entity

Type

Severity

Impact

Seen

Blog Details

Supply Chain Source

Incident Details

View

Taro Pharmaceutical...

Breach

3/2023

TAR937072825

Loading…

A.I.

Taro Pharmaceuticals Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Actual

Prediction

Incident Predictions locked

Access Monitoring Plan

A.I Risk Score Likelihood 3 - 6 - 9 months

Actual

Prediction A

Prediction B

Prediction C

Prediction D

A.I. Risk Score Predictions locked

Access Monitoring Plan

Loading…

Underwriter Stats for Taro Pharmaceuticals

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Taro Pharmaceuticals in 2026.

Incidents vs All-Companies Average (This Year)

No incidents recorded for Taro Pharmaceuticals in 2026.

Incident Types Taro Pharmaceuticals vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Taro Pharmaceuticals in 2026.

Incident History - Taro Pharmaceuticals (X = Date, Y = Severity)

Loading…

SUBSIDIARY

Taro Pharmaceuticals Subsidiaries

Taro Pharmaceuticals

Pharmaceutical Manufacturing

Website: http://www.taro.com

Company Size: 1,518

Alchemee (formerly The Proactiv Company)Wellness and Fitness Services

TARO PHARMACEUTICALS CANADAPharmaceutical Manufacturing

Taro Pharmaceutical IndustriesPharmaceutical Manufacturing

Loading…

Taro Pharmaceuticals Similar Companies

Eli Lilly and Company

lilly.com

We're a medicine company turning science into healing to make life better for people around the world. It all started nearly 150 years ago with a clear vision from founder Colonel Eli Lilly: "Take what you find here and make it better and better." Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing science to solve some of the world's most significant health challenges. General Information and Guidelines: When you engage with us on LinkedIn, you're agreeing to these Community Guidelines: https://e.lilly/guidelines. If you have questions about a Lilly medicine, contact The Lilly Answers Center at 1-800-Lilly-Rx (1-800-545-5979) Monday through Friday, excluding company holidays.

Merck

merck.us

At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities. For more information, visit www.merck.com. This site is intended for residents of the United States and Canada and their territories only. FLS: http://merck.us/3TKXNuZ

Zoetis

zoetis.com

The world’s leading animal health company. We’ve been innovating ways to predict, prevent, detect, and treat animal illness for over 70 years, and we continue to stand by those raising and caring for animals worldwide – from veterinarians and pet owners to livestock farmers. Our leading portfolio and pipeline makes a difference in over 100 countries. Community Guidelines: This page is intended to share how Zoetis is advancing care for animals. We aspire to create a supportive community, but there are guidelines to which posts and comments on this page must adhere. If your post references a side effect related to any Zoetis product, we may contact you for more information. To monitor the safety of Zoetis products, we advise you to call our Veterinary Medical Information and Product Support Team at 1-888-963-8471; Support Team is available Mon-Fri 9am to 6:30pm ET. We reserve the right to remove any post/comment that violates LinkedIn Guidelines. As a last resort, we reserve the right to block users that demonstrate a repeated pattern of violating LinkedIn’s spirit of constructive, professional discourse. We respectfully request that you refrain from posting comments including: Unsolicited and/or unverified medical advice Vulgarity and/or profanity Discriminatory and/or derogatory comments, hate speech Politics and religion Personal attacks and/or threats Promotion of illegal activity Copyright/trademark infringements Topics that may be considered spam/advertising Our regular business hours are Mon-Fri 9am to 5pm ET. Zoetis does not endorse and is not responsible for information and opinions shared by community members. The information shared is provided for educational purposes only and is not intended to replace discussions with an animal healthcare professional. Testimonials represent individual experience only and the experiences and opinions of community members may be unique to the speaker. Terms of Use: https://www.zoetis.com/terms-of-use

PT Kalbe Farma, Tbk

kalbe.co.id

Established in 1966, PT Kalbe Farma Tbk. (“the Company” or “Kalbe”) has gone a long way from its humble beginnings as a garage-operated pharmaceutical business in North Jakarta. It has expanded by strategic acquisitions of pharmaceutical companies, building a leading brand positioning and reaching to international markets to transform itself into an integrated consumer health and nutrition enterprise to promote its mission to improve health for a better life. Kalbe expands its business interests and transformed itself to become a provider of an integrated healthcare solution through its 4 business divisions: the Prescription Pharmaceutical Division, Consumer Health Division, Nutritionals Division and Distribution and Logistics Division. These business divisions manage an extensive portfolio of prescription pharmaceuticals and OTC drugs, energy drink and nutrition products, as well as a robust distribution arm serving over one million outlets across Indonesia’s vast archipelago. In the international market, the Company has established its footprint in ASEAN countries, Nigeria, and South Africa, positioning Kalbe as a national pharmaceutical company with a competitive edge in the export market. Kalbe Farma has established a robust research and development activities in leading edge generic drug formulation and continuous development of innovative consumer and nutritional products. Through strategic alliances with international partners, Kalbe have also started to support several successful research and development venture working on cancer drugs, stem cells and biotechnology research. With 17,000 employees, Kalbe Farma is the largest healthcare provider in Indonesia, with unrivaled marketing, branding, distribution, financial strength and research and development expertise. Kalbe Farma is also the largest publicly-listed pharmaceutical company in Southeast Asia, commanding a market capitalization of Rp71.0 trillion and sales turnover Rp21.0 trillion by end of 2018.

Astellas Pharma

astellas.com

Astellas is a global life sciences company committed to turning innovative science into VALUE for patients. We provide transformative therapies in disease areas that include oncology, ophthalmology, urology, immunology and women's health. Through our research and development programs, we are pioneering new healthcare solutions for diseases with high unmet medical need. Visit our Global Astellas LinkedIn Community Guidelines to learn more about interacting with this page: https://www.astellas.com/en/global-linkedin-community-guidelines

Zydus Group

zyduslife.com

The Zydus Group with an overarching purpose of empowering people with freedom to live healthier and more fulfilled lives, is an innovative, global life-sciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. The group employs over 27000 people worldwide and is driven by its mission to unlock new possibilities in life-sciences through quality healthcare solutions that impact lives. The group aspires to transform lives through pathbreaking discoveries.

Alembic Pharmaceuticals Limited

alembic-india.com

Established in 1907, Alembic Pharmaceuticals Limited is a leading pharmaceutical company in India. The Company is vertically integrated with the ability to develop, manufacture and market pharmaceutical products, pharmaceutical substances and Intermediates. Alembic is the market leader in the Macrolides segment of anti-infective drugs in India. Alembic's manufacturing facilities are located in Vadodara and Baddi in Himachal Pradesh. The plant at Vadodara has the largest fermentation capacity in India. The Panelav facility houses the API and formulation manufacturing (both US FDA approved) plants. The plant at Baddi, Himachal Pradesh manufactures formulations for the domestic and non-regulated export market. The company has a state of the art Research Centre at Vadodara.

UCB

cb ucb.com

At UCB, we believe everyone deserves to live the best life they can - as free as possible from the challenges and uncertainty of disease. Our purpose is to support people living with severe central nervous system and immunological conditions by delivering meaningful solutions that go beyond medicine. We are driven by the experiences of patients and caregivers, and inspired to pursue innovations that create real value - not just in clinical outcomes, but in everyday moments, dreams pursued, and simple pleasures enjoyed. Our ambition is to unlock transformative science and technologies that respond to unmet needs and elevate lives. From our headquarters in Belgium to nearly 40 countries around the world, we nurture a culture of respect and care. By listening deeply and collaborating across borders and disciplines, we enable cutting-edge research shaped by patients’ needs. Through strong connections with healthcare professionals, partners, and communities, we strive to make a lasting impact - today and into the future. We're inspired by patients, driven by science.

Intas Pharmaceuticals

intaspharma.com

Intas is one of the leading multinational pharmaceutical formulation development, manufacturing, and marketing organization in the world. It has been growing at 19% CAGR and crossed the $2.5 billion mark in the past financial year. The company has set up a network of subsidiaries, under the name Accord Healthcare in the EU, US, Canada, SA, Australia, APAC as well as CIS & MENA regions. Intas is present in 85+ countries, with more than 70% of its revenue coming from global business. Currently ranked 6th in the Indian pharmaceutical market, it’s the largest privately owned Indian generic pharma company. Intas has established leadership in key therapeutic segments like CNS, Cardio, Diabeto, Gastro, Urology, Oncology & Animal Health in India. We are among the top 10 generic players in the highly regulated markets of EU, US & UK. Intas operates 17 advanced formulations, R&D, and distribution facilities, of which 10 are in India and the rest in the UK, Mexico & Greece with the help of our 23,000+ Human Capital. Between them, the facilities are accredited by global regulators such as USFDA, EMA, MHRA, TGA, and others. The company invests ~6-7% of its revenues in R&D and has over 10,000 product registrations worldwide with a strategic pipeline of 300+ high-value FTF/FTM, Biosimilars, and NDDS products. Intas' highly advanced EU-GMP Certified Biopharma division is fueled by a mission to provide affordable “Biosimilars for Billions” across niche segments such as oncology, auto-immune, ophthalmology, nephrology, rheumatology, and hormone-based therapies. The Plasma Fractionation Unit of Intas Pharmaceuticals is a pioneer in manufacturing plasma-derived therapeutics. It houses a full-fledged R&D lab and a state-of-the-art WHO-GMP-certified manufacturing facility complemented with a GLP-compliant QC lab. Our values of Innovation, Customer Delight, Ownership & Collaboration, Performance Focus & Care for Society are the driving forces toward excellence.

Loading…

NEWS

Taro Pharmaceuticals CyberSecurity News

Latest updates, reports, and threat intel affecting the global network.

December 04, 2025 08:00 AM

Taro Pharmaceutical: How To Find & Own America's Greatest Opportunities

Drugmaker Taro Pharmaceutical was one of the rare exceptions of a stock that advanced while the S&P 500 descended into a bear market.

Read Article

October 28, 2025 07:00 AM

Sun Pharma Defeats Taro Investor Suit Over Take-Private Deal

A Taro Pharmaceutical Industries Ltd. investor failed to adequately allege the generic drugmaker or its then-suitor Sun Pharmaceutical...

Read Article

June 25, 2024 09:11 AM

Sun Pharma Completes $348 Mn Merger with Israel’s Taro Pharma

Sun Pharma successfully completes a mega MN merger with Israel's Taro Pharm, marking a significant move in the global pharmaceutical industry and further...

Read Article

January 21, 2024 08:00 AM

Taro to become wholly owned by Sun Pharma

India's Sun Pharmaceutical Industries will pay $43 per share for the 21.5% of Taro that it does not already own. Taro employs 1550 people in...

Read Article

January 18, 2024 08:00 AM

Sun Pharma to acquire Taro shares for $347.73m

Sun Pharmaceutical has signed a definitive merger agreement for the acquisition of all outstanding ordinary shares of Taro Pharmaceutical not currently owned...

Read Article

November 16, 2023 08:00 AM

US drops price-fixing case against former Taro Pharmaceutical executive

US prosecutors on Thursday asked a federal judge to dismiss charges in Pennsylvania against a former sales and marketing executive of Taro Pharmaceutical...

Read Article

May 27, 2023 07:00 AM

Taro Pharmaceuticals class action alleges company responsible for data breach

Taro Pharmaceuticals was negligent with its employees' data, leading to their private information being leaked in a cyberattack, a new class...

Read Article

March 06, 2023 08:00 AM

Sun Pharma suffers IT breach, says core systems not affected

Mumbai, India-based Sun Pharma disclosed an IT security breach. The company quickly isolated the affected systems and is investigating the situation.

Read Article

November 30, 2021 10:40 AM

Judge OKs $75M Sun, Taro Pharma generic drug price-fixing settlement

A judge signed off a settlement to end price-fixing claims against Sun Pharma and Taro Pharmaceutical Industries USA Inc.

Read Article

Loading…

CVE

Latest

Global CVEs (Not Company-Specific)

CVE-2026-8718

SUMMARY

tls_opt_dtls_peer_connection_id_value_get() in subsys/net/lib/sockets/sockets_tls.c, which handles getsockopt(SOL_TLS, TLS_DTLS_PEER_CID_VALUE), passed the caller-supplied optval directly to mbedtls_ssl_get_peer_cid() without verifying the buffer was at least MBEDTLS_SSL_CID_OUT_LEN_MAX (default 32) bytes. mbedtls_ssl_get_peer_cid() copies the peer-negotiated DTLS Connection ID (length 1..MBEDTLS_SSL_CID_OUT_LEN_MAX) into that buffer without a destination-size parameter, so a caller-supplied optlen smaller than the CID causes a write of up to 31 bytes past the buffer end. In CONFIG_USERSPACE builds the getsockopt syscall verifier (z_vrfy_zsock_getsockopt) bounce-buffers the user's optval into a kernel allocation of exactly optlen bytes (k_usermode_alloc_from_copy -> z_thread_malloc), so an unprivileged user thread that passes a small optlen on a connected DTLS socket with Connection ID enabled induces a kernel-heap buffer overflow, with the overflowing content being the remote peer's CID. The defect requires CONFIG_MBEDTLS_SSL_DTLS_CONNECTION_ID, an established DTLS session with a negotiated peer CID, and (for the kernel-crossing case) CONFIG_USERSPACE. Introduced when the TLS_DTLS_CID option was added (v3.5.0). The fix rejects callers whose optlen is below MBEDTLS_SSL_CID_OUT_LEN_MAX with -EINVAL.

Published

Date2026-08-10

Updated

Date2026-08-10

RISK INFORMATION (Score: 8.4)

cvss3

Base Score: 8.4

Complexity: LOW

CVSS:3.1/AV:L/AC:L/PR:L/UI:N/S:C/C:N/I:H/A:H

Impact Score

5.8

Exploitability

REFERENCES

CVE-2026-48161

SUMMARY

react18-use is a React 19 use hook shim. Between 2026-05-19 01:07:01 and 2026-05-19 15:20:43, the default branch contained malicious commits 7b79148d1495a2505f9277da295a98cf176f4496 through 7b79148d1495a2505f9277da295a98cf176f4496 that executed remote attacker-controlled code on developer machines during `npm install`. The commits were removed by force-push, but local clones, forks, and direct-SHA URLs may still contain them, and `npm install` against an affected checkout will still execute the code today. The package was not published to npm. `src/install.js` was added and wired into the `postinstall` script. It fetched a JavaScript payload from an attacker-controlled HTTPS endpoint (configurable via an environment variable), disabled TLS verification, and evaluated the response as code with `require` available. Execution was deliberately skipped on CI and cloud/serverless environments, targeting developer workstations. The second-stage payload was attacker-hosted and cannot be reconstructed. Assume full compromise of anything reachable from a Node process with the user's permissions. Those who ran `npm install` against an affected checkout on a developer machine on or after 2026-05-19 01:07:01 should treat the machine as compromised, rotate every credential the machine could reach, audit account activity since 2026-05-19 01:07:01, and clean local clones.

Published

Date2026-08-10

Updated

Date2026-08-10

RISK INFORMATION (Score: )

cvss4

Base Score: 9.3

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:H/VI:H/VA:H/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

Exploitability

REFERENCES

https://github.com/dai-shi/react18-use/security/advisories/GHSA-32xh-vg5f-64fm

CVE-2026-11812

SUMMARY

The UpdateHub management subsystem (subsys/mgmt/updatehub/updatehub.c) drives every update operation through a single file-scope ctx structure that holds the CoAP block context, payload buffer, status code, socket, and a one-element poll-fd array fds[1]. Access to ctx was not serialized, and prepare_fds() wrote ctx.fds[ctx.nfds] and incremented ctx.nfds with no bounds check. Two independent paths mutate ctx concurrently: the background autohandler running on the system workqueue, and user-triggered operations reached through the updatehub run shell command, direct API calls, or — since the operations are exposed as syscalls — userspace threads. When a second flow enters prepare_fds() while ctx.nfds is already 1, the write lands one element past the array; by struct layout it overlaps the adjacent ctx.sock/ctx.nfds members. More broadly, the unsynchronized sharing lets two flows interleave connection setup and teardown, double-closing a socket descriptor or scribbling the shared buffers. The result is corruption of the update subsystem's internal state and denial of service of the firmware-update path; the out-of-bounds write is contained within the ctx structure and there is no demonstrated path to memory outside it or to code execution. Triggering requires a local actor able to invoke update operations (or, with CONFIG_USERSPACE, an unprivileged userspace thread) and to win a timing race against the background handler; remote peers cannot control the race timing. The fix serializes the entry points with a mutex and adds a bounds check to prepare_fds().

Published

Date2026-08-10

Updated

Date2026-08-10

RISK INFORMATION (Score: 2.5)

cvss3

Base Score: 2.5

Complexity: HIGH

CVSS:3.1/AV:L/AC:H/PR:L/UI:N/S:U/C:N/I:N/A:L

Impact Score

1.4

Exploitability

REFERENCES

CVE-2026-11811

SUMMARY

The UpdateHub over-the-air update client's start_coap_client() in subsys/mgmt/updatehub/updatehub.c leaks the CoAP/DTLS socket descriptor on its connection-setup failure paths. The shared error: cleanup gated socket closing on a ret > 0 flag, but ret was set to -1 immediately after the socket was created, so when zsock_setsockopt() (DTLS) or zsock_connect() subsequently failed the gate was false and cleanup_connection() was never called. The open descriptor in the global ctx.sock was then overwritten by the next attempt, permanently leaking it from the socket / net_context pool until reboot. The failing setup path is reached every time the OTA client tries to contact the UpdateHub server and the connection cannot be established — driven automatically by the periodic autohandler() poll (and on demand via the updatehub_probe()/updatehub_update() API or the updatehub run shell command). The DTLS handshake/connect outcome is influenceable by a network or on-path attacker who drops, resets, or otherwise disrupts traffic to the server, and also fails naturally whenever the server is unreachable. Each failed attempt permanently leaks one descriptor; once the shared socket pool is exhausted, networking degrades device-wide until the device is rebooted, a denial-of-service condition. Severity is low because the leak rate is bounded by the configured OTA poll interval (default once per 24 hours), the effect is gradual and recovered by reboot, and only builds with the UpdateHub client enabled are affected. There is no memory-corruption, information-disclosure, or authentication impact.

Published

Date2026-08-10

Updated

Date2026-08-10

RISK INFORMATION (Score: 3.7)

cvss3

Base Score: 3.7

Complexity: HIGH

CVSS:3.1/AV:N/AC:H/PR:N/UI:N/S:U/C:N/I:N/A:L

Impact Score

1.4

Exploitability

2.2

REFERENCES

CVE-2025-30241

SUMMARY

Certain web interface components in affected TP-Link Aginet devices do not validate and sanitize user-supplied input properly before passing it to system-level command execution functions. An authenticated adjacent attacker may inject specially crafted input to execute arbitrary operation system commands with elevated privileges. Successful exploitation may allow execution of arbitrary system commands, potentially leading to full device compromise.

Published

Date2026-08-10

Updated

Date2026-08-10

RISK INFORMATION (Score: )

cvss4

Base Score: 8.6

Complexity: LOW

CVSS:4.0/AV:A/AC:L/AT:N/PR:L/UI:N/VC:H/VI:H/VA:H/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

Exploitability

REFERENCES

https://www.tp-link.com/us/support/faq/5239/

Loading…

API

Access Data Using Our API

Get company history

curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'

Try It API Documentation Rapid

MEASURE

What Do We Measure ?

Incident

Finding

Grade

Digital Assets

Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.

These are some of the factors we use to calculate the overall score:

Network SecurityIdentify exposed access points, detect misconfigured SSL certificates, and uncover vulnerabilities across the network infrastructure.

SBOM (Software Bill of Materials)Gain visibility into the software components used within an organization to detect vulnerabilities, manage risk, and ensure supply chain security.

CMDB (Configuration Management Database)Monitor and manage all IT assets and their configurations to ensure accurate, real-time visibility across the company's technology environment.

Threat IntelligenceLeverage real-time insights on active threats, malware campaigns, and emerging vulnerabilities to proactively defend against evolving cyberattacks.

Rankiteo

By Rankiteo

★ ★ ★ ★ ★

View on G2.com

Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.

View latest plans →View all security reports →

MILESTONEG

Users
Love Us

Loading…